Marc C Chamberlain
Overview
Explore the profile of Marc C Chamberlain including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
244
Citations
6959
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kumthekar P, Grimm S, Aleman R, Chamberlain M, Schiff D, Wen P, et al.
Neurooncol Adv
. 2022 Oct;
4(1):vdac123.
PMID: 36225651
Background: Systemic therapies for refractory meningiomas are limited with no FDA-approved therapeutics. Vascular endothelial growth factor (VEGF) is a signaling protein associated with neovascularization, peritumoral edema, and meningioma tumorigenesis. Methods:...
2.
3.
4.
Arvold N, Armstrong T, Warren K, Chang S, DeAngelis L, Blakeley J, et al.
Neuro Oncol
. 2018 May;
20(7):897-906.
PMID: 29788429
Background: Corticosteroids are the mainstay of treatment for peritumor edema but are often associated with significant side effects. Therapies that can reduce corticosteroid use would potentially be of significant benefit...
5.
Taillibert S, Chamberlain M
Handb Clin Neurol
. 2018 Jan;
149:169-204.
PMID: 29307353
Leptomeningeal metastasis (LM) results from dissemination of cancer cells to both the leptomeninges (pia and arachnoid) and cerebrospinal fluid (CSF) compartment. Breast cancer, lung cancer, and melanoma are the most...
6.
7.
Chowdhary S, Damlo S, Chamberlain M
Cancer Control
. 2017 May;
24(1):S1-S16.
PMID: 28557973
Background: Neoplastic meningitis, also known as leptomeningeal disease, affects the entire neuraxis. The clinical manifestations of the disease may affect the cranial nerves, cerebral hemispheres, or the spine. Because of...
8.
Chamberlain M, Kim B
J Neurooncol
. 2017 May;
133(3):561-569.
PMID: 28500559
A single institution retrospective evaluation of nivolumab following disease progression on bevacizumab in adults with recurrent glioblastoma (GBM) with an objective of determining progression free survival (PFS). There is no...
9.
Warren K, Vezina G, Poussaint T, Warmuth-Metz M, Chamberlain M, Packer R, et al.
Neuro Oncol
. 2017 Apr;
20(1):13-23.
PMID: 28449033
Lack of standard response criteria in clinical trials for medulloblastoma and other seeding tumors complicates assessment of therapeutic efficacy and comparisons across studies. An international working group was established to...
10.
Chamberlain M, Colman H, Kim B, Raizer J
J Neurooncol
. 2017 Feb;
131(3):507-516.
PMID: 28204914
There is no standard therapy for recurrent anaplastic glioma (AG). Salvage therapies include alkylator-based chemotherapy, re-resection with or without carmustine implants, re-irradiation and bevacizumab. Bendamustine is a novel bifunctional alkylator...